Business Context and Reporting Period
Palisade Bio, Inc. (PALI) filed a Form 8-K on August 10, 2026, to announce its financial results for the three and six months ended June 30, 2026. The company is incorporated in Delaware and trades on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not included in the provided text.
Material Changes
The filing does not disclose specific material changes versus prior periods. The document serves solely as a notification that results for the period ended June 30, 2026, have been issued.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies and unusual items. Such information is referenced as being available in the attached press release (Exhibit 99.1).
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific revenue, net loss, and cash burn figures for the three and six months ended June 30, 2026.
- Verify year-over-year comparisons and any updates to clinical trial milestones or operational progress mentioned in the press release.
- Confirm the company's current cash position and runway estimates provided in the full financial disclosure.
- Check for any new risk factors or legal contingencies disclosed in the full press release text.